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A Novel GJB2 Mutation p.Asn54His in a Patient with
Palmoplantar Keratoderma, Sensorineural Hearing Loss
and Knuckle Pads
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TO THE EDITOR
Mutations in the GJB2 gene encoding
connexin26 are the major cause of
autosomal-recessive or -dominant non-
syndromic congenital sensorineural
hearing loss (SNHL) (Kelsell et al.,
1997; Kenneson et al., 2002; refer to
the connexin-deafness homepage at
http://davinci.crg.es/deafness/). In addi-
tion, connexin26 mutations have been
identified in autosomal-dominant syn-
dromic congenital SNHL with palmo-
plantar keratoderma (PPK) (Maestrini
et al., 1999; Richard et al., 2002,
2004; Brown et al., 2003; van Steensel
et al., 2004; Arita et al., 2006). We have
encountered a Japanese boy with PPK,
knuckle pads and congenital SNHL and
GJB2 mutation analysis revealed a
novel mutation p.Asn54His.
The patient was a 12-year-old Japa-
nese boy with PPK, knuckle pads on the
fingers and severe SNHL. He had a
congenital onset of profound bilateral
SNHL. At 1 year of age, he developed
PPK and knuckle pads. There was
no familial history of skin disorders
or auditory dysfunction. At age 12,
moderate PPK was seen. Knuckle
pads were apparent on all his
fingers (Figure 1a and b). Acneiform
follicular keratotic papules were seen
on his forehead and face, although
these acneiform papules might just be
acne. No mutilation (pseudoainhum)
was seen on the fingers. Nails, hair,
and teeth were normal and no
leukonychia was observed. Ophthal-
mologic examination revealed no ap-
parent abnormality.
The medical ethical committee at
Hokkaido University approved all
studies described below. The study
was conducted according to the De-
claration of Helsinki Principles. Partici-
pants or their legal guardian gave their
written informed consent. The coding
region of GJB2 (Genbank accession no.
NM 004004) was amplified from geno-
mic DNA by PCR, as described pre-
viously (Richard et al., 1998). Direct
sequencing of the patient’s PCR pro-
ducts revealed that the patient was a
heterozygote for a novel missense
mutation p.Asn54His (A to C substitu-
tion at nucleotide position 160: aspar-
agine 54 (AAC) to histidine (CAC)) in
GJB2 (Figure 1d), which was not
found in his mother. We were unable
to obtain a DNA sample from his
father. This mutation was not found in
100 normal unrelated Japanese allelesAbbreviations: PPK, palmoplantar keratoderma; SNHL, sensorineural hearing loss
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(50 normal unrelated Japanese indivi-
duals) by direct sequence analysis and
was unlikely to be a polymorphism
(data not shown). Direct sequencing of
all the exons and exon/intron borders
of GJB2 failed to detect any other
pathogenic mutation in the patient’s
DNA.
A skin biopsy obtained from the
palmar lesion revealed orthohyperker-
atosis and mild regular acanthosis.
Electron microscopy of the upper epi-
dermal keratinocytes showed normal
morphology with normal keratin net-
work and keratohyalin granules. Gap
junctions existed in all living epidermal
layers, and the morphology of gap
junctions was normal, showing a typi-
cal pentalaminar structure, 20 nm in
width (Figure 1e).
Immunofluorescent stainings with
rabbit polyclonal anti-connexin26 anti-
body (the epitope is a portion of the
cytoplasmic loop of connexin26)
(ZYMED Laboratories, San Francisco,
CA) showed strong connexin26 expres-
sion in the upper layers of the wide rete
ridge in the patient’s palmar epidermis
(Figure 1f), compared with weak con-
nexin26 expression in the normal pal-
mar epidermis (Figure 1g). The antibody
used in this study binds to both normal
and mutated connexin26 peptides. Thus,
it was not clear whether the overex-
pressed connexin26 in the patient’s
epidermis was normal and/or mutated.
Connexin43 immunostainings with
mouse monoclonal anti-connexin43 anti-
body (clone 4E6.2) (Chemicon Interna-
tional, Temecula, CA) revealed that the
expression of connexin43 was almost
completely membranous and appeared
similar both in the patient’s and normal
control skin (data not shown).
Bart–Pumphrey syndrome is charac-
terized by knuckle pads, PPK, SNHL,
and leukonychia (Bart and Pumphrey,










Figure 1. The patient’s clinical features, GJB2 mutation, gap junction ultrastructure and upregulated
connexin26 expression. (a–c) The patient’s clinical features at the age of 12. (a) Severe knuckle pads were
seen over all the fingers. (b) The knuckle pads were sharply demarcated, hyperkeratotic plaques. (b) Nails
were not involved. (c) Hyperkeratotic plaques resembling knuckle pads were seen in the toes and
periphery of the foot. (d) Mutation in connexin26 gene (GJB2). A novel heterozygous A to C substitution
at the codon 54 (c.160A4C) was detected in the patient’s genomic DNA. This mutation leads to the
amino-acid substitution, p.Asn54His. (e) A gap junction with normal, typical pentalaminar structure,
20 nm in width, was observed in the periphery of the keratinocyte in the lesional epidermis on the palm.
Arrows, gap junction; arrowhead, desmosome. (f) Upregulated connexin26 expression was seen in the
spinous layers of the patient’s lesional skin in the palm. (g) In the normal control palmar skin, weak
connexin26 immunostaining (green) was observed in the spinous layers (white arrows). Connexin26
immunostaining, green (FITC); nuclear staining, red (propidium iodide). (e) Bar¼ 100 nm and (g) 50 mm.
Table 1. Mutations within the first extracellular domain of connexin26 and associated clinical features
Syndromes KID syndrome Knuckle pads, PPK, and SNHL VWS PPK and SNHL
Causative mutations p.Ala40Val p.Asp50Asn/Tyr p.Asn54Lys p.Asn54His1 p.Gly59Arg/Ser p.Asp66His p.Gly59Ala p.Arg75Trp/Gln
Knuckle pads   + + +   
PPK + + + + + + + +
SNHL + + + + + + + +
Nail dystrophy
(leukonychia)
+ + 7     
Keratitis + +      
Pseudoainhum      +  
KID, keratitis–ichthyosis–deafness; PPK, palmoplantar keratosis; SNHL, sensorineural hearing loss; VWS, Vohwinkel syndrome; +, observed; , not observed
or not described; 7, observed in some case, but not in the others.
1Present case.
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diagnosed with Bart–Pumphrey syn-
drome because of a lack of nail
involvement. In two families which
were reported as suffering from Bart–-
Pumphrey syndrome and harboring
GJB2 mutations, an affected patient in
one family did not show any leukony-
chia and, in the other family, two
affected family members showed leuko-
nychia, but the other three failed to
show any leukonychia (Alexandrino
et al., 2005; Leonard et al., 2005). In
this context, leukonychia is not an
essential clinical feature in the patients
with knuckle pad formation, PPK, and
SNHL. It is questionable whether
Bart–Pumphrey syndrome having leu-
konychia as an essential characteristic/
diagnostic feature is a distinct clinical
entity from the knuckle pads, PPK, and
SNHL phenotype. Thus, in this study,
we have adopted the clinical
entity ‘‘knuckle pads, PPK, and SNHL’’,
instead of Bart–Pumphrey syndrome.
Most pathogenic GJB2 mutations
causing both SNHL and skin manifesta-
tions cluster in the first extracellular
loop of the connexin26 peptide
(Richard et al., 1998, 2004; Maestrini
et al., 1999; Heathcote et al., 2000;
Uyguner et al., 2002; Oshima et al.,
2003; Yotsumoto et al., 2003; Mont-
gomery et al., 2004; Alexandrino et al.,
2005; Leonard et al., 2005). This fact
clearly suggests that this extracellular
domain is important for the correct
formation and/or function of gap junc-
tions. Indeed, the evolutionary con-
served, first extracellular loop domain
was reported to play an essential role in
the assembly of connexon hemichan-
nels, connexon–connexon interactions,
voltage gating, and channel permeabil-
ity (Rubin et al., 1992; White et al.,
1995; Oshima et al., 2003).
The causative GJB2 missense muta-
tions in the previously reported three
families showing knuckle pads, PPK,
and SNHL were a replacement of
glycine 59 in two families (Alexandrino
et al., 2005; Leonard et al., 2005) and a
replacement of asparagine 54 in the
other family (Richard et al., 2004), both
in the evolutionary conserved first
extracellular loop of connexin26. In
the present case, the GJB2 mutation
similarly lay in the asparagine 54
residue. Asparagine was replaced by
histidine in the present case and by
lysine in the previously reported Bart–
Pumphrey syndrome family (Richard
et al., 2004). Asparagine is an acidic
amino acid and histidine and lysine are
basic amino acids. Thus, the amino-
acid exchange would probably result in
an altered electron charge at the muta-
tion site and may lead to defective
voltage gating affecting the formation
and function of gap junctions. In addi-
tion, histidine has a relatively large,
aromatic side chain, and the amino-
acid change may lead to a conforma-
tional change of the first extracellular
domain in the present case. To deter-
mine the effect of this mutation on
cell–cell gap junction function, func-
tional studies by expressing the mutant
allele in cultured cells are necessary.
Among the mutations located in the
first extracellular loop of connexin26,
differences in the site and nature of the
mutations are thought to lead to the
distinctive clinical phenotypes, as shown
in Table 1 and Figure 2. These data
including our case suggest that alterations
of the amino-acid residues asparagines
54 and glycine 59 in the central portion
of the first extracellular loop might be
associated with the clinical knuckle pad
feature, although we do not have any
direct evidence to support that the
mutations caused knuckle pads. Further
accumulation of the similar cases should
be needed to conclude this mutation lead
to knuckle pads.
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Figure 2. Connexin26 molecular structure, mutations and their associated skin syndromes. Connexin26
gene (GJB2) mutations associated with syndromic SNHL cluster in the N-terminal portion of connexin26,
mainly in the first extracellular loop. Note all the mutations associated with knuckle pads affect
asparagines 54 or glycine 59. Asterisk represents the present case.
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Colchicine Promotes Antigen Cross-Presentation by Murine
Dendritic Cells
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TO THE EDITOR
Colchicine (COL) is a microtubule
depolymerizing drug that has been
widely used for the treatment of many
inflammatory skin diseases, such as
Behc¸et disease, psoriasis, palmoplantar
pustulosis, Sweet’s syndrome, and leu-
kocytoclastic vasculitis (Sullivan et al.,
1998; Bibas et al., 2005). With regard
to its pharmacological mechanisms of
action, COL is thought to primarily
inhibit various functions of polymor-
phonuclear neutrophils, including
mitosis, adhesion, migration, and pha-
gocytosis (Keller et al., 1984; Cronstein
et al., 1995; Blocker et al., 1997; Jordan
and Wilson, 2004). We recently re-
ported totally unexpected pharmacolo-
gical activities of COL (Mizumoto et al.,
2005). Briefly, COL at relatively low
concentrations triggered phenotypic
maturation of murine bone marrow
(BM)-derived dendritic cells (DCs) as
well as their production of several
cytokines and chemokines. Moreover,
BM-DCs pretreated with COL exhibited
enhanced capacities to activate allo-
geneic T cells and to present a foreign
protein antigen to immunologically
naive CD4 T cells. Interestingly, COL
pretreatment markedly improved the
ability of BM-DCs to uptake FITC-
conjugated dextran (DX). Upon local
injection in low doses, COL promoted
in situ maturation and mobilization
of epidermal Langerhans cells and
boosted both humoral and cellular
immune responses in mice (Mizumoto
et al., 2005). These observations may
appear to be rather contradictory to the
conventional view that COL acts as an
anti-inflammatory agent (when admi-
nistered systemically at high doses).
Thus, we first sought to study in vitro
effects of COL on human DCs.
For this purpose, we employed hu-
man DC preparations generated from
CD34þ progenitors in the cord blood.
Following 24-hour pretreatment with
3 mg/ml COL, we examined surface
expression of major histocompatibility
complex (MHC) class II molecules,
CD83, and co-stimulatory molecules
CD40, CD80, and CD86 within the
CD1aþ populations. COL treatment
significantly elevated the expression of
all tested markers of DC maturation
without affecting their viability (Figure 1a).
Abbreviations: BM, bone marrow; COL, colchicine; DC, dendritic cell; DX, dextran; ER, endoplasmic
reticulum; MHC, major histocompatibility complex; OVA, ovalbumin; TAP, transporter associated with
antigen presentation
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